EpiCept Corporation to Present at Two Upcoming Investor Conferences

EpiCept Corporation to Present at Two Upcoming Investor Conferences

    EpiCept Corporation (Nasdaq: EPCT and STO: EPCT) today announced
that Jack Talley, President and CEO, will be presenting at the 2008
BIOCOM Investor Conference on October 28, 2008 from 11:30-11:55 a.m.
local time at the Hyatt Regency La Jolla in San Diego, California. Mr.
Talley will also present at the Rodman & Renshaw Annual Global
Investor Conference on November 10, 2008 from 10:20 - 10:45 a.m. local
time at the New York Palace Hotel in New York.

    Both presentations will be available live via webcast for 90 days
thereafter. The webcasts can be accessed by visiting www.epicept.com.

    About EpiCept Corporation

    EpiCept is focused on unmet needs in the treatment of cancer and
pain. The Company's broad portfolio of pharmaceutical product
candidates includes Ceplene, a cytokine immunomodulator that recently
received marketing authorization in Europe for the remission
maintenance of AML patients, and several pain therapies in clinical
development. In addition, EpiCept's ASAP technology, a proprietary
live cell high-throughput caspase-3 screening technology, can
efficiently identify new cancer drug candidates and molecular targets
that selectively induce apoptosis in cancer cells. Two oncology drug
candidates currently in clinical development that were discovered
using this technology have also been shown to act as vascular
disruption agents in a variety of solid tumors.

    Forward-Looking Statements

    This news release and any oral statements made with respect to the
information contained in this news release, contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include statements
which express plans, anticipation, intent, contingency, goals,
targets, future development and are otherwise not statements of
historical fact. These statements are based on EpiCept's current
expectations and are subject to risks and uncertainties that could
cause actual results or developments to be materially different from
historical results or from any future results expressed or implied by
such forward-looking statements. Factors that may cause actual results
or developments to differ materially include: the risk that Ceplene
will not be launched in Europe in the first quarter of 2009 or achieve
significant commercial success, the risk that we are unable to find a
suitable marketing partner for Ceplene on attractive terms, a timely
basis or at all, the risk that any post-approval clinical study will
not be successful, the risk that EpiCept will not be able to maintain
its final regulatory approval or marketing authorization, the risk
that Myriad's development of Azixa(TM) will not be successful, the
risk that Azixa will not receive regulatory approval or achieve
significant commercial success, the risk that we will not receive any
significant payments under our agreement with Myriad, the risk that
the development of our other apoptosis product candidates will not be
successful, the risk that our ASAP technology will not yield any
successful product candidates, the risk that clinical trials for NP-1
or EPC2407 will not be successful, the risk that NP-1 or EPC2407 will
not receive regulatory approval or achieve significant commercial
success, the risk that our other product candidates that appeared
promising in early research and clinical trials do not demonstrate
safety and/or efficacy in larger-scale or later stage clinical trials,
the risks associated with the adequacy of our existing cash resources,
our need to raise additional financing to continue to meet our capital
needs and our ability to continue as a going concern, the risks
associated with our ability to continue to meet our obligations under
our existing debt agreements or that we may default on our loans or
that our lenders may declare the Company in default, the risk that we
will not obtain approval to market any of our product candidates other
than Ceplene(R), the risk that the Company's securities may be
delisted by The Nasdaq Capital Market or the OMX Nordic Exchange, the
risks associated with dependence upon key personnel, the risks
associated with reliance on collaborative partners and others for
further clinical trials, development, manufacturing and
commercialization of our product candidates; the cost, delays and
uncertainties associated with our scientific research, product
development, clinical trials and regulatory approval process; our
history of operating losses since our inception; the highly
competitive nature of our business; risks associated with litigation;
risks associated with prior material weaknesses in our internal
controls; and risks associated with our ability to protect our
intellectual property. These factors and other material risks are more
fully discussed in EpiCept's periodic reports, including its reports
on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities
and Exchange Commission. You are urged to carefully review and
consider the disclosures found in EpiCept's filings, which are
available at www.sec.gov or at www.epicept.com. You are cautioned not
to place undue reliance on any forward-looking statements, any of
which could turn out to be wrong due to inaccurate assumptions,
unknown risks or uncertainties or other risk factors.

    *Azixa is a registered trademark of Myriad Genetics, Inc.

    EPCT-GEN

EpiCept Corporation
             Robert W. Cook, 914-606-3500
             rcook@epicept.com
             or
             Investors:
             Lippert/Heilshorn & Associates
             Kim Sutton Golodetz, 212-838-3777
             kgolodetz@lhai.com
             or          Bruce Voss, 310-691-7100
             bvoss@lhai.com
             or
             Media:
             Feinstein Kean Healthcare
             Greg Kelley, 617-577-8110
             gregory.kelley@fkhealth.com